ѻý

<ѻý class="page-title">Meeting Coverage

TCTM

<ѻý class="page-description">Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Too

"Viable" option for patients eligible for umbilical cord blood transplantation, investigator says

TCTM over a photo of Salt Palace Convention Center, Salt Lake City, UT
<ѻý class="section_title">Latest TCTM Meeting Coverage
Promising Data for Allo-Transplant After CAR T-Cell Failure in LBCL

Durable responses with no unexpected or prolonged safety issues

April 27, 2022
Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS

1-year relapse-free survival rate of 60% with maintenance therapy after transplant

April 25, 2022
Bringing Transplant to More Patients With AML

Conditioning with radiolabeled antibody leads to successful transplantation in 84% of older patients

February 25, 2020
New CAR-T Makes Case for Aggressive Lymphomas

Largest trial to date shows 73% ORR, 53% CR, potential for outpatient treatment

February 25, 2020
Stem-Cell Transplant Trial Ends in a Draw

Similar PFS with haploidentical bone marrow, double unrelated umbilical cord blood

February 24, 2020
Preemptive Anti-IL-6 May Cut Severe CRS With CAR-T Tx

Targeting patients with high tumor burden reduced severe CRS by 50%

February 22, 2020
Myeloablative Therapy Prevails in AML Transplant Study

Better survival, fewer relapses compared with reduced-intensity conditioning

February 21, 2020
Better Quality CR With One AML Therapy vs Another?

Longer survival after CR/CRi with CPX-351 than with 7+3 in patients with AML-MRC

February 21, 2020